当前位置:首页>产品中心>单抗/多抗>Anti-Nipah virus/NiV F/Fusion glycoprotein F0 Recombinant Antibody |抗尼帕病毒/NiV F/融合糖蛋白F0重组抗体(靶标:尼帕病毒融合糖蛋白F0)

Anti-Nipah virus/NiV F/Fusion glycoprotein F0 Recombinant Antibody |抗尼帕病毒/NiV F/融合糖蛋白F0重组抗体(靶标:尼帕病毒融合糖蛋白F0)

  • 货号:RB9TVK521073
  • 价格:面议
  • 点击:540

产品介绍

产品参数

形态Liquid
宿主种属Mouse
克隆性Monoclonal
抗体亚型IgG2a, kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
内毒素水平Please contact with the lab for this information.
应用ELISA, Neutralization
种属反应性Nipah viurs
靶标F, Fusion glycoprotein F0, Fusion glycoprotein F1, Fusion glycoprotein F2, Protein F
储存缓冲液0.01M PBS pH 7.4
稳定性和储存Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
产品使用说明ELISA: 1:2000-1:20000
登录号Q9IH63
背景信息

Fusion glycoprotein F0 (Fusion protein) is a ~60 kDa protein. Class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and plasma cell membrane fusion, the heptad repeat (HR) regions assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and plasma cell membranes. Directs fusion of viral and cellular membranes leading to delivery of the nucleocapsid into the cytoplasm.

备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Camrelizumab Neutralizing Recombinant Antibody |抗卡瑞利珠单抗中和重组抗体(靶标:卡瑞利珠单抗中和抗体) 592
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 394
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 622
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 350
Anti-Golimumab Neutralizing Recombinant Antibody |抗戈利木单抗中和重组抗体(靶标:戈利木单抗中和抗体) 496
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 638
Anti-Infliximab Non-Neutralizing Recombinant Antibody |抗英夫利昔单抗非中和重组抗体(靶标:英夫利昔单抗非中和抗体) 596
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 689
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 523
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 348
Anti-Infliximab Neutralizing Recombinant Antibody |抗英夫利昔单抗中和重组抗体(靶标:英夫利昔单抗中和抗体) 482
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 387
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 614
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 574
Anti-Matuzumab Neutralizing Recombinant Antibody |抗马妥珠单抗中和重组抗体(靶标:马妥珠单抗中和抗体) 540
Anti-Elotuzumab Non-Neutralizing Recombinant Antibody|抗埃罗妥珠单抗非中和重组抗体(靶标:埃罗妥珠单抗非中和抗体) 661
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 366
Anti-Elotuzumab Neutralizing Recombinant Antibody |抗埃罗妥珠单抗中和重组抗体(靶标:埃罗妥珠单抗中和抗体) 395
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 367
Anti-Oleclumab Neutralizing Recombinant Antibody |抗奥乐克单抗中和重组抗体(靶标:奥乐克单抗中和抗体) 393
总计 33037 个记录,共 1652 页,当前第 1649 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00